

**Patients with synchronous or metachronous peritoneal carcinomatosis arising from colorectal or appendiceal cancer**

**Inclusion/exclusion criteria**

**Eligible/written informed consent**

*Not eligible*

**Preoperative chemotherapy, 3 months**  
(FOLFOX/FOLFIRI + Cetuximab)

**Expl. Laparotomy/Laparoscopy**

**CRS (CC-0/1)**

**HIPEC (300 mg/m<sup>2</sup> Oxaliplatin ip plus  
400 mg/m<sup>2</sup> 5-FU and 20 mg/m<sup>2</sup> FA iv)**

*Incomplete CR  
Palliative surgery*

**Postoperative chemotherapy, 3 months**  
(FOLFOX/FOLFIRI + Cetuximab)

**3-monthly Follow-up,  
24 months**